Sentence: We analyzed 129 non-Hodgkin lymphoma patients who underwent AHSCT from 1996 to 2013 using the most common regimens : CBV ( cyclophosphamide , carmustine and etoposide ; n = 16 ) , BEAM ( carmustine , etoposide , cytarabine and melphalan ; n = 36 ) and BEAC ( carmustine , etoposide , cytarabine and cyclophosphamide ; n = 77 ) .
Drug combination annotation:
[{'class': 'POS', 'spans': ['cyclophosphamide', 'carmustine', 'etoposide'], 'is_context_needed': True}, {'class': 'POS', 'spans': [3, 4, 5, 6], 'is_context_needed': True}, {'class': 'POS', 'spans': [8, 9, 10, 7], 'is_context_needed': True}]